On June 12, 2025, Sangamo Therapeutics stockholders approved the Amended 2018 Equity Incentive Plan, which increases the number of shares available for issuance by 14 million and the maximum for stock options by 28 million shares, totaling 123.2 million shares. The event also included the election of directors and ratification of independent auditors.